Primo Capital SGR invests in MT Ortho S.r.l.

Primo Capital SGR's acquisition of a significant stake in MT Ortho S.r.l., a leading provider of implantable devices for spinal neurosurgery and orthopedics, strategically aligns with its objective to support and accelerate technological and commercial growth in small and medium-sized Italian healthcare companies. With €65 million raised by Primo Health, the private equity fund aims to bolster MT Ortho's market presence through financial and operational support. The transaction involves a series of capital contributions that enable MT Ortho to scale up its production capacity and expand into international markets, particularly the EU and North America. The company’s proprietary technology in trabecular titanium cages and microsphere systems for vertebral fractures places it at the forefront of regenerative medicine innovation. This strategic investment will help MT Ortho accelerate its product development pipeline and penetrate high-growth regions with advanced orthopedic devices. This deal shifts competitive dynamics within the global orthopedic device market, estimated to grow from $53 billion in 2024 to over $75 billion by 2033. By securing substantial financial backing, MT Ortho gains a competitive edge against established players in terms of technological advancement and market expansion. The integration of Primo Capital’s expertise in healthcare and its extensive network offers significant growth opportunities for MT Ortho. Post-close, key challenges include managing regulatory compliance across international markets and ensuring smooth product launches. However, with robust financial support and strategic guidance from Primo Health, MT Ortho is well-positioned to capitalize on the growing demand for innovative medical solutions in orthopedic care.